Sichuan Kelun-biotech Biopharmaceutical Co., Ltd.

This study tests a new drug called SKB571 in people with advanced non-small cell lung cancer. The goal is to see if it is safe and can shrink tumors. About 295 participants will receive the drug until their cancer gets worse or side effects become too severe.

This study tests a new drug called SKB571 in 60 adults with advanced non-small cell lung cancer that has specific MET gene changes and has worsened after standard treatments. Participants receive SKB571 alone to see if it shrinks tumors and how safe it is. The goal is to control …

This early-phase study tests the safety and best dose of SKB315, a drug designed to attack cancer cells with a specific protein called Claudin18.2. About 246 adults with advanced solid tumors that haven't responded to standard treatments will receive the drug. The goal is to see …

This phase 3 study tests a new drug called SKB264 against standard chemotherapy in 376 people with advanced HR+/HER2- breast cancer that has not responded to at least one prior chemo. The goal is to see if SKB264 can slow cancer growth and improve survival. Participants are rando…

This study tests a new drug called A166 in people with HER2-positive breast cancer that has spread and no longer responds to certain previous treatments. About 40 adults aged 18 to 75 will receive A166 to see if it shrinks tumors or slows the disease. The goal is to find a better…

This study tests an experimental drug called SKB518, given alone or with standard chemotherapy, in people with advanced ovarian, cervical, or endometrial cancer that has not responded to other treatments. The goal is to see if the drug can shrink tumors or slow cancer growth. Abo…

This early-phase study tests a new drug called MK-6204 (SKB535) in about 90 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. This is a first-in-hu…

This early-phase study tests a new drug called SKB571 in about 138 adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goal is to check the drug's safety and find the right dose. Researchers will also look for early signs that the drug shr…

This early-stage trial tests a new drug called SKB107 in people with advanced solid tumors that have spread to the bones. The main goal is to check the drug's safety and how the body processes it. About 90 adults aged 18 to 75 who have run out of standard treatment options may jo…

This study tests a new drug, SKB103, in people with advanced solid tumors who have run out of standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors or slow their growth. About 277 adults aged 18 to 75 will take part.

This early-phase study tests an experimental drug, SKB445, in 126 adults with advanced solid tumors that have not responded to or are not eligible for standard treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also watch for any sig…

This study tests a new drug called SKB264 against standard chemotherapy as the first treatment for people with advanced triple-negative breast cancer that cannot be removed by surgery. The trial includes about 524 adults whose tumors do not have a certain protein (PD-L1) or who h…

This study tests a new drug called SKB105 in people with advanced solid tumors who have run out of standard treatments. The goal is to see if the drug is safe and can shrink tumors. About 256 adults aged 18 to 75 will take part in this early-phase trial.

This study is for people with a specific type of lung cancer (EGFR-mutated) that can be removed with surgery. It tests whether giving a new drug, sacituzumab tirumotecan, alone or with another drug (osimertinib) before surgery can shrink the tumor more effectively. About 60 adult…

This study tests a new drug called SKB518 in 192 adults with lung cancer (non-small cell or small cell). The goal is to see if it shrinks tumors and to check for side effects. Participants receive the drug alone until their disease gets worse or side effects become too severe.

This study tests a new drug combination (SKB500) in 80 adults with small cell lung cancer, a fast-growing type of lung cancer. The goal is to see if the treatment is safe and can shrink tumors or slow the disease. Participants must be 18-75 and have extensive-stage cancer, with s…

This study tests a new drug, SKB264, combined with an immunotherapy drug (KL-A167) with or without chemotherapy in 110 adults with advanced or metastatic non-small cell lung cancer. The goal is to see if the combination is safe and can shrink tumors. Participants must have a spec…

This study tests whether adding SKB264 to the standard drug osimertinib helps people with a specific type of advanced lung cancer (EGFR-mutated non-squamous non-small cell) live longer without their cancer growing. About 420 adults who have not had prior treatment for advanced di…

This early-stage study tests a new drug called SKB500 in 180 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and side effects, and to see if it can shrink tumors. Researchers will also measure how the d…

This study tests a new drug called SKB264 against standard chemotherapy in people with advanced hormone receptor-positive, HER2-negative breast cancer that has stopped responding to hormone therapy. About 430 adults aged 18-75 will be randomly assigned to receive either SKB264 or…

This study tests whether adding the experimental drug SKB264 to the immunotherapy pembrolizumab works better than standard chemotherapy plus pembrolizumab for people with advanced non-squamous lung cancer that lacks the PD-L1 protein. About 432 adults with stage IIIB/IV disease w…

This study tests a new drug called SKB518 for the first time in humans. It is for adults with advanced solid tumors that have stopped responding to standard treatments or have no effective therapy available. The main goals are to check the drug's safety, find the best dose, and s…

This early-stage study tests a new medicine called SKB575 in healthy volunteers and people with moderate-to-severe atopic dermatitis (eczema). The main goals are to check safety and see if the drug can reduce eczema symptoms, like itching and skin redness. About 90 participants w…